Bristol Myers Squibb (BMY) Announces Amphista Therapeutics Collaboration

Bristol Myers Squibb (BMY) announced a strategic collaboration with Amphista Therapeutics to discover and develop small molecule protein degraders, which grants Bristol Myers a global exclusive license to the degraders. Targeted protein degradation (TPD) therapeutics remove pathogenic proteins from the body to potentially offer access to disease targets previously considered "undruggable".